DMP Stock Overview Manufactures and sells off-patent branded pharmaceutical products in Germany. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Dermapharm Holding SE Competitors Price History & Performance
Summary of share price highs, lows and changes for Dermapharm Holding Historical stock prices Current Share Price €39.60 52 Week High €41.90 52 Week Low €29.90 Beta 1.1 1 Month Change 3.94% 3 Month Change 27.54% 1 Year Change 1.69% 3 Year Change -42.48% 5 Year Change 5.66% Change since IPO 41.43%
Recent News & Updates
Dermapharm Holding SE to Report Fiscal Year 2024 Results on Mar 14, 2025 Jan 02
Third quarter 2024 earnings released: EPS: €0.60 (vs €0.46 in 3Q 2023) Nov 17
Second quarter 2024 earnings released: EPS: €0.32 (vs €0.17 loss in 2Q 2023) Aug 28
Price target decreased by 12% to €50.13 Jun 27
New major risk - Financial position May 19
Dermapharm Holding SE to Report Q1, 2024 Results on May 15, 2024 May 09 See more updates
Dermapharm Holding SE to Report Fiscal Year 2024 Results on Mar 14, 2025 Jan 02
Third quarter 2024 earnings released: EPS: €0.60 (vs €0.46 in 3Q 2023) Nov 17
Second quarter 2024 earnings released: EPS: €0.32 (vs €0.17 loss in 2Q 2023) Aug 28
Price target decreased by 12% to €50.13 Jun 27
New major risk - Financial position May 19
Dermapharm Holding SE to Report Q1, 2024 Results on May 15, 2024 May 09
Full year 2023 earnings released: EPS: €1.16 (vs €2.49 in FY 2022) Mar 29
Dermapharm Holding SE, Annual General Meeting, Jun 27, 2024 Mar 28
Dividend of €0.88 announced Mar 17
Dermapharm Holding SE to Report Fiscal Year 2023 Results on Mar 28, 2024 Mar 14
New minor risk - Financial position Nov 19
Third quarter 2023 earnings released: EPS: €0.46 (vs €0.98 in 3Q 2022) Nov 17
Second quarter 2023 earnings released: €0.17 loss per share (vs €0.27 profit in 2Q 2022) Aug 30
Investor sentiment improves as stock rises 15% Aug 17
Upcoming dividend of €1.05 per share at 2.3% yield Jun 08
Full year 2022 earnings: EPS and revenues miss analyst expectations Mar 30
Price target decreased by 9.9% to €56.40 Mar 15
Price target decreased to €60.60 Jan 07
Third quarter 2022 earnings released: EPS: €0.98 (vs €1.15 in 3Q 2021) Nov 17
Price target decreased to €64.60 Nov 16
Investor sentiment improved over the past week Nov 12
Investor sentiment deteriorated over the past week Sep 17
Second quarter 2022 earnings released: EPS: €0.27 (vs €0.74 in 2Q 2021) Sep 09
Dermapharm Holding SE Announces Executive Changes Sep 09 Dermapharm Holding SE Provides Earnings Guidance for the Full Year 2022
Upcoming dividend of €2.17 per share May 26
First quarter 2022 earnings: EPS and revenues miss analyst expectations May 19
Dermapharm Holding SE Provides Earnings Guidance for the Full Year 2022 May 19
Full year 2021 earnings: EPS exceeds analyst expectations Apr 14 Dermapharm Holding SE Re-Affirm Earnings Guidance for the Year 2022
Dermapharm Holding SE (XTRA:DMP) completed the acquisition of C³ - Cannabinoid Compound Company Gmbh from Canopy Growth Corporation (TSX:WEED). Feb 02
Dermapharm Holding SE (XTRA:DMP) completed the acquisition of C³ - Cannabinoid Compound Company Gmbh from Canopy Growth Corporation (TSX:WEED). Feb 01
Price target increased to €102 Jan 05
Price target increased to €98.50 Dec 17 Dermapharm Holding SE (XTRA:DMP) entered into an agreement to acquire C3 - Cannabionoid Compound Company GmbH from Canopy Growth Corporation (TSX:WEED) for approximately €120 million.
Price target increased to €94.17 Nov 18
Third quarter 2021 earnings released: EPS €1.15 (vs €0.42 in 3Q 2020) Nov 17
Price target increased to €89.50 Nov 11
Second quarter 2021 earnings released: EPS €0.74 (vs €0.22 in 2Q 2020) Sep 08
Upcoming dividend of €0.88 per share Jun 17
First quarter 2021 earnings released May 21
Dermapharm Confirms Earnings Guidance for 2021 May 19
Price target increased to €82.71 Apr 20
Full year 2020 earnings released: EPS €1.59 (vs €1.43 in FY 2019) Apr 16
Price target increased to €79.20 Apr 15
Dermapharm Holding SE Provides Revenue Guidance for Fiscal 2021 Apr 15
Investor sentiment improved over the past week Apr 13
Price target increased to €76.60 Apr 09
Price target increased to €72.60 Mar 29
Dermapharm Holding SE Expects the Collaboration with BioNTech SE for the Production of the Covid-19 Vaccine Comirnaty Feb 13
New 90-day high: €63.52 Feb 13
New 90-day high: €60.63 Jan 15
New 90-day high: €58.27 Dec 29
Market bids up stock over the past week Nov 25
New 90-day high: €50.44 Nov 20
Price target raised to €54.00 Nov 19
Third quarter 2020 earnings released: EPS €0.42 Nov 17
Revenue and earnings miss expectations Nov 17
Market bids up stock over the past week Nov 09
New 90-day low: €40.88 Oct 29
New 90-day high: €47.33 Oct 05
First half earnings released Sep 12
New 90-day high - €46.96 Sep 11
New 90-day low - €42.72 Jul 30 Shareholder Returns DMP DE Pharmaceuticals DE Market 7D -0.4% 4.0% 3.0% 1Y 1.7% -12.8% 13.2%
See full shareholder returns
Return vs Market: DMP underperformed the German Market which returned 13.1% over the past year.
Price Volatility Is DMP's price volatile compared to industry and market? DMP volatility DMP Average Weekly Movement 5.3% Pharmaceuticals Industry Average Movement 5.4% Market Average Movement 4.8% 10% most volatile stocks in DE Market 10.8% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: DMP has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: DMP's weekly volatility (5%) has been stable over the past year.
About the Company Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany. The company operates through three segments: Branded Pharmaceuticals and Other Healthcare Products, Parallel Import Business, and Herbal Extracts. It offers branded generics, OTC products, non-prescription healthcare products, and herbal extracts and parallel-imported originator pharmaceuticals.
Show more Dermapharm Holding SE Fundamentals Summary How do Dermapharm Holding's earnings and revenue compare to its market cap? DMP fundamental statistics Market cap €2.18b Earnings (TTM ) €90.59m Revenue (TTM ) €1.17b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) DMP income statement (TTM ) Revenue €1.17b Cost of Revenue €439.61m Gross Profit €734.32m Other Expenses €643.74m Earnings €90.59m
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Mar 14, 2025
Earnings per share (EPS) 1.68 Gross Margin 62.55% Net Profit Margin 7.72% Debt/Equity Ratio 174.1%
How did DMP perform over the long term?
See historical performance and comparison Dividends
2.2% Current Dividend Yield
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/21 04:39 End of Day Share Price 2025/01/21 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Dermapharm Holding SE is covered by 11 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Gerhard Orgonas Berenberg Daniel Wendorff Commerzbank AG Fabian Piasta Jefferies LLC
Show 8 more analysts 
